Category Archives: venture captial

Mystic moldy pizza: Food for thought from Allicense 2014

SAN FRANCISCO – When talking trends in biopharma there’s no shortage of metaphors – Tuesday’s health care debate, for example, went for the timely baseball terms, referencing singles and home runs – or oft-overused industry buzzwords, of which the recent…

Share

Bubbleology and Biotech’s Bull Run

Our recent analysis of biotech’s second quarter performance showed, for public biotech companies at least, their bull run that began more than 18 months ago is showing no signs of slowing down. Since the beginning of 2012 the Nasdaq Biotechnology…

Share

What Global Financial Crisis? Capital Markets Back Biotechs

It is that time of year again when we take the pulse of the industry at the close of the third quarter. Overall we find that it is performing well, more so for public biotechs than private ones. Despite the…

Share

Biotech Fundraising Slows in 1H12, Tougher Times Ahead?

There is no doubt that 2011 was a hot financing year for biotech and it was always going to be a tough act to follow. Well the industry followed the script to the letter. According to a BioWorld Insight analysis,…

Share

Profit vs. Value: When Activist Shareholders Attack

Amylin Pharmaceuticals Inc.’s board dodged a dissident shareholder bullet three years ago, but the San Diego-based biotech is back in the crosshairs of billionaire investor and activist shareholder Carl Icahn, who again is seeking to nominate a new slate of…

Share

Biotech Fundraising Dips in Q112, But No Need to Panic

I’m seeing lots of references to BioWorld’s recent analysis by Cynthia Robbins-Roth showing that U.S.-based, VC-backed biotechs raised $391 million in the first quarter, a 34 percent increase compared to the same period last year. That’s good news, especially given…

Share

Defining Specialty Pharma: What is it, Can it Innovate, and Does it Matter?

The article I wrote last week for FierceBiotech on the relationship between Series A funding and innovation led to an interesting discussion with Bruce Booth, partner at Atlas Venture and biotech blogger extraordinaire. The crux of my article was this:…

Share

He Said What?!?! Best Biotech Quotes of 2011

As BioWorld Insight readers know, our “Word on the Street” column provides a sample of the most entertaining and thought-provoking quotes our staff stumbles upon each week. Some are gathered during interviews, some gleaned from analyst reports, and some overheard…

Share

Send Me an Angel: More VC Alternatives on the Rise

It seems to me that an increasing number of start-ups have been boot-strapping their way through preclinical without venture capital lately. I have no quantitative data to back this up. But it’s a feeling I had earlier this year, too,…

Share